Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF-α Inhibitory Activity

Journal of Medicinal Chemistry

Volumn 46, Issue 24, 2003, Pages 5222-5229

  Zhu, Xiaoxiang ^a   Giordano, Tony ^b,e   Yu, Qian Sheng ^a   Holloway, Harold W ^a   Perry, Tracy Ann ^a   Lahiri, Debomoy K ^c   Brossi, Arnold ^d   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b Message Pharmaceuticals Inc   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 3 THIOXO 2 (2 OXO 6 THIOXO 3 PIPERIDINYL) 1H ISOINDOL 1 ONE; 2,3 DIHYDRO 3 THIOXO 2 (2,6 DITHIOXO 3 PIPERIDINYL) 1H ISOINDOL 1 ONE; DITHIOGLUTARIMIDE; DRUG ANALOG; MESSENGER RNA; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THIOTHALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANGIOGENESIS; ARTICLE; CELL VIABILITY; CHEMICAL MODIFICATION; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHEMA NODOSUM LEPROSUM; EVALUATION; MONONUCLEAR CELL; MULTIPLE MYELOMA; RNA STABILITY; STRUCTURE ANALYSIS;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE; GENES, REPORTER; HUMANS; LIPOPOLYSACCHARIDES; LUCIFERASES; MICE; MONOCYTES; PIPERIDINES; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; THALIDOMIDE; THIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242691672     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030152f     Document Type: Article

References (45)

1. Eger, K.; Jalalian, B.; Verspohl, E. J.; Lupke, N.-P. Synthesis, central nervous system activity and teratogenicity of a homothalidomide. Arzneim. Forsch. 1990, 40, 1073-1075.
2. Sheskin, J. Thalidomide in the treatment of lepra reaction. Clin. Pharmacol. Ther. 1965, 6, 303.
3. Kumar, S.; Witzig, T. E.; Rajkumar, S. V. Thalidomide as an anti-cancer agent. J. Cell Mol. Med. 2002, 6, 160-174.
4. Richardson, P.; Hideshima, T.; Anderson, K. Thalidomide: emerging role in cancer medicine. Annu. Rev. Med. 2002, 53, 628-657.
5. Sampaio, E. P.; Sarno, E. N.; Gallily, R.; Cohn, Z. A.; Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J. Exp. Med. 1991, 173, 699-703.
6. Kruys, V.; Marinx, O.; Shaw, G.; Deschamps, J.; Huez, G. Translational blockade imposed by cytokine-derived UA-rich sequences. Science 1989, 245 (4920) Aug 25, 1989, 852-855.
7. Moreira, A. L.; Sampaio, E. P.; Zmuidzinas, A.; Frindt, P.; Smith, K. A. ; Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J. Exp. Med. 1993, 177, 1675-1680.
8. Haslett, P.; Corral, L.; Albert, M.; Kaplan, G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Expl. Med. 1998, 187, 1885-1889.
9. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide in an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. 1994, 91, 4082-34085.
10. Figg, W. D.; Kruger, E. A.; Price, D. K.; Kim, S.; Dahut, W. D. Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer. Invest. New Drugs 2002, 20, 183-194.
11. MacFarlane, M. TRAIL-induced signaling and apoptosis. Toxicol. Lett. 2003, 139, 89-97.
12. Lamhamedi-Cherradi, S. E.; Zheng, S. J.; Maguschak, K. A.; Peschon, J.; Chen, Y. H. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat. Immunol. 2003, 4, 207-208.
13. Thanos, D.; Maniatis, T. NFkB: a lesson in family values. Cell 1995, 80, 529-532.
14. Begg, A. A.; Baltimore, D. An essential role of NFkB in preventing TNF-α-induced cell death. Science 1996, 274, 782-784.
15. Bauer, K. S.; Dixon, S. C.; Figg, W. D. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 1998, 55, 1827-1834.
16. Meierhofer, C.; Wiedermann, C. J. New insights into the pharmacological and toxicological effects of thalidomide. Curr. Opin. Drug Discovery Dev. 2003, 6, 92-99.
17. Price, D. K.; Ando, Y.; Kruger, E.; Weiss, M.; Figg, W. D. 5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis Ther. Drug Monit. 2002, 24, 104-110.
18. Kling, J. Redeeming thalidomide. Modern Drug Discovery 2000, 3, 35-36.
19. Muller, G. W.; Corral, L. G.; Shire, M. G.; Wang, H.; Moreira, A.; Kaplan, G.; Stirling, D. I. Structural modifications of thalidomide produce analogues with enhanced tumor necrosis factor inhibitory activity. J. Med. Chem. 1996, 39, 3238-3240.
20. Muller, G. W.; Shire, M. G.; Wong, L. M.; Corral, L. G.; Patterson, R. T.; Chen, Y.; Stirling, D. I. Thalidomide analogs and PDE4 inhibition. Bioorg. Med. Chem. Lett. 1998, 8, 2669-2674.
21. Muller, G. W.; Chen, R.; Huang, S.-Y.; Corral, L. G.; Wong, L. M.; Patterson, R. T.; Chen, Y.; Kaplan, G.; Stirling, D. I. Amino-substitutes thalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett. 1999, 9, 1625-1630.
22. Hashimoto, Y. Structural development of biological response modifiers based on thalidomide. Bioorg. Med. Chem. 2002, 10, 461-479.
23. Teubert, U.; Zwingenberger, K.; Stephan, W.; Eger, K. 5′-Substituted thalidomide analogs as modulators of TNF-α Arch. Pharm. Pharm. Med. Chem. 1998, 331, 7-12.
24. Luzzio, F. A.; Thomas, E. M.; Figg, W. D. Thalidomide metabolites and analogs. part 2: cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine. Tetrahedron Lett. 2000, 41, 7151-7155.
25. Niwayama, S.; Turk, B. E.; Liu, J. O. Potent inhibition of tumor necrosis factor a production by tetrafluorothalidomide and tetrafluorophthalimides. J. Med. Chem. 1996, 39, 3044-3045.
26. Weinz, C.; Blaschke, G. Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis. J. Chromatogr., B: Biomed. Sci. Appl. 1995, 674, 287-292.
27. Shan, J. H.; Swartz, G. M.; Papathanassiu, A. E.; Treston, A. M.; Fogler, W. E.; Madsen, J. W.; Green, S. J. Synthesis and enantiomeric separation of 2-phthalimido-glutaric acid analogues: potent inhibitors of tumor metastasis. J. Med. Chem. 1999, 42, 3014-3017.
28. Cava, M. P.; Levinson, M. I. Thionation reaction of Lawesson's reagents. Tetrahedron 1985, 41, 5061-5087.
29. Flaih, N.; Pham-Huy, C.; Galons, H. An expeditious synthesis of cyclic imides. Tetrahedron Lett. 1999, 40, 3697-3698.
30. Milewska, M. J.; Bytner, T.; Polonski, T. Synthesis of lactams by regioselective reduction of cyclic dicarboximides. Synthesis 1996, 12, 1485-1488
31. Gossauer, A.; Roebler, F.; Zilch, H. Einige Präprrative Anwendungen der reaktion von N-(thioacyl)urethanen und deren vinylogen mit resonanzstabilisierten phosphor-yliden. Liebigs Ann. Chem. 1979, 9, 1309-1321.
32. Cherkasov, R. A.; Kutyrev, G. A.; Pudovik, A. N. Organothiophosphorus reagents in organic synthesis. Tetrahedron 1985, 41, 2567-2624.
33. Iyer, S.; Kontoyiannis, D.; Chevrier, D.; Woo, J.; Mori, N.; Cornejo, M. ; Kollias, G.; Buelow, R. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J. Biol. Chem. 2000, 275, 17051-17057.
34. Prichett, W.; Hand, A.; Shields, J.; Dunnington, D. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor-α. J. Inflammation 1995, 45, 97-105.
35. Kruys, V.; Huez, G. Translational control of cytokine expression by 3′ AU-rich sequences. Biochemie 1994, 76, 862-866.
36. Chen, C.-Y. A.; Shyu, A.-B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biol. Sci. 1995, 20, 465-470.
37. Rajagopalan, LE.; Malter, J. S. Growth factor-mediated stabilization of amyloid precursor protein mRNA is mediated by a conserved 29-nucleotide sequence in the 3′-untranslated region. J. Neurochem. 2000, 74, 52-59.
38. Lahiri, D. K.; Chen, D.; Vivien, D.; Ge, Y.-W.; Greig, N. H.; Rogers, J. T. Role of cytokines in the gene expression of amyloid §-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J. Alzheimer's Dis. 2003, 5, 81-90.
39. Rogers, J. T.; Leiter, L.; Mcphee, J.; Cahill, C. M.; Zhan, S. S.; Potter, H.; Nilsson, L. N. Translation of the Alzheimer amyloid precursor protein mRNA is upregulated by interleukin 1 through 5′-untranslated region sequences. J. Biol. Chem. 1999, 274, 6421-6431.
40. Rogers, J. T.; Randall, J. D.; Cahill, C.; Eder, P. S.; Huang, X.; Gunshin, H.; Sarang, S.; Utsuki, T.; Greig, N. H.; Lahiri, D. K.; Tanzi, R. E.; Bush, A. I.; Giordano, T.; Gullans, S. R. An iron-responsive element type II in the 5′ untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 2002, 277, 45518-45528.
41. Shaw, K. T. Y.; Utsuki, T.; Rogers, J. T.; Yu, Q. S.; Sambamurti, K.; Brossi, A.; Ge, Y. W.; Lahiri, D. K.; and Greig, N. H. Phenserine regulates translation of b-amyloid precursor mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7605-7610.
42. Dingwall, C.; Ernberg, I.; Gait, M. J.; Green, S. M.; Heaphy, S.; Karn, J.; Lowe, A. D.; Singh, M.; Skinner, M. A.; Valerio, R. Human immunodeficiency virus 1 tat protein binds transactivation-responsive region (TAR) RNA in vitro. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 6925-6929.
43. Fujita, J.; Mestre, J. R.; Zeldis, K.; Subbaramaiah, K.; Dannenberg, A. J. Thalidomide and its analogues inhibit lipopolysacharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. 2001, 7, 3349-3355.
44. Sheng, H.; Shao, J.; Dixon, D. A.; Williams, C. S.; Prescott, S. M.; DuBois, R. N.; Beauchamp, R. D. Tranforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stablization of mRNA. J. Biol. Chem. 2000, 275, 6628-6635.
45. Neininger, A.; Kontoyiannis, D.; Kotlyarov, A.; Winzen, R.; Eckert, R.; Volk, H. D.; Holtmann, H.; Kollias, G.; Gaestel, M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different posttranscriptional levels. J. Biol. Chem. 2002, 277, 3065-3068.